Page last updated: 2024-10-25

cilostazol and Obesity

cilostazol has been researched along with Obesity in 4 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Cilostazol treatment significantly induced the messenger RNA and protein expression of PCSK9 in HepG2 cells and enhanced PCSK9 promoter activity."5.72Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. ( Chang, HY; Chao, TH; Chen, PW; Lee, CH; Tseng, SY, 2022)
" Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up."2.78Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013)
"Intermittent claudication is a form of exercise intolerance characterized by muscle pain during walking in patients with peripheral artery disease (PAD)."1.40Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. ( Alcantara, R; Baltgalvis, KA; Claypool, MD; Friera, AM; Godinez, G; Goff, D; Gururaja, T; Hansen, D; Hitoshi, Y; Jenkins, Y; Kinsella, TM; Lang, W; Lau, D; Li, W; Li, Y; Markovtsov, V; McCaughey, K; McLaughlin, J; Nguyen, H; Pan, A; Park, G; Payan, DG; Shaw, SJ; Singh, BK; Singh, R; Smith, IJ; Sun, TQ; Uy, G; White, K, 2014)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Chen, PW1
Tseng, SY1
Chang, HY1
Lee, CH1
Chao, TH1
Wada, T1
Onogi, Y1
Kimura, Y1
Nakano, T1
Fusanobori, H1
Ishii, Y1
Sasahara, M1
Tsuneki, H1
Sasaoka, T1
Baltgalvis, KA1
White, K1
Li, W1
Claypool, MD1
Lang, W1
Alcantara, R1
Singh, BK1
Friera, AM1
McLaughlin, J1
Hansen, D1
McCaughey, K1
Nguyen, H1
Smith, IJ1
Godinez, G1
Shaw, SJ1
Goff, D1
Singh, R1
Markovtsov, V1
Sun, TQ1
Jenkins, Y1
Uy, G1
Li, Y1
Pan, A1
Gururaja, T1
Lau, D1
Park, G1
Hitoshi, Y1
Payan, DG1
Kinsella, TM1
Gao, W1
Zhang, Q1
Ge, H1
Guo, Y1
Zhou, Z1

Trials

1 trial available for cilostazol and Obesity

ArticleYear
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
    Angiology, 2013, Volume: 64, Issue:7

    Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H

2013

Other Studies

3 other studies available for cilostazol and Obesity

ArticleYear
Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
    International journal of molecular sciences, 2022, Aug-29, Volume: 23, Issue:17

    Topics: Animals; Cilostazol; Lipids; Mice; Mice, Obese; Obesity; PPAR gamma; Proprotein Convertase 9; Propro

2022
Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
    European journal of pharmacology, 2013, May-05, Volume: 707, Issue:1-3

    Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Chronic Disease; Cilostazol; Diabetes Mellitus, E

2013
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
    American journal of physiology. Heart and circulatory physiology, 2014, Apr-15, Volume: 306, Issue:8

    Topics: Aging; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Arginine; Cilostazol; Diet, High-F

2014